Literature DB >> 10629622

Equine sarcoid tumour treated by autogenous tumour vaccine.

R E Kinnunen1, T Tallberg, H Stenbäck, S Sarna.   

Abstract

Twenty-one horses with sarcoid tumours were treated by bio-immunotherapy using autogenous vaccines during 1991-1997. At operation the base of the tumour was left in the skin and autovaccines were made from extirpated tumour tissue by polymerization. The horses thus formed their own internal control group. One of 12 horses having a primary tumour, and four of 9 horses suffering recurrent tumours, prior to bio-immunotherapy, developed single recurrences. Four of these five horses suffering recurrence were treated anew, leading to remission. Disease-free intervals were longer for primary (P = 0.0005) and recurrent sarcoids (P = 0.0156) than for conventional surgery alone. Mitochondrial events seem to effect the healing.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10629622

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009-2014).

Authors:  Caitlin C Rothacker; Ashley G Boyle; David G Levine
Journal:  Can Vet J       Date:  2015-07       Impact factor: 1.008

Review 2.  Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.

Authors:  Virgil Schijns; Alberto Fernández-Tejada; Žarko Barjaktarović; Ilias Bouzalas; Jens Brimnes; Sergey Chernysh; Sveinbjorn Gizurarson; Ihsan Gursel; Žiga Jakopin; Maria Lawrenz; Cristina Nativi; Stephane Paul; Gabriel Kristian Pedersen; Camillo Rosano; Ane Ruiz-de-Angulo; Bram Slütter; Aneesh Thakur; Dennis Christensen; Ed C Lavelle
Journal:  Immunol Rev       Date:  2020-06-28       Impact factor: 12.988

3.  Malignant melanoma in a grey horse: case presentation and review of equine melanoma treatment options.

Authors:  Lucy Va Metcalfe; Peter J O'Brien; Stratos Papakonstantinou; Stephen D Cahalan; Hester McAllister; Vivienne E Duggan
Journal:  Ir Vet J       Date:  2013-11-06       Impact factor: 2.146

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.